Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to find out if people with Prader-Willi syndrome have a difference in the protein which changes inactive cortisone to the active stress hormone cortisol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome

NCT02368379

Prader Willi Syndrome Adrenal Insufficiency

COMPLETED NA

Oxytocin Trial in Prader-Willi Syndrome

NCT02013258

Prader Willi Syndrome

COMPLETED PHASE1

Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia

NCT00004669

Bronchopulmonary Dysplasia

COMPLETED PHASE2

Assessment of CAI in Adults With PWS.

NCT04700644

Central Adrenal Insufficiency Prader-Willi Syndrome

COMPLETED

Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome

NCT01479322

Prader-Willi Syndrome Obesity

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prader-Willi Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PWS not receiving Growth Hormone

No interventions assigned to this group

Control subjects healthy or obese

No interventions assigned to this group

PWS subjects starting Growth Hormone

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prader-Willi syndrome confirmed by molecular testing, ages 6 months to adult
* Controls: Age-matched, sex-matched, developmentally normal, BMI-controlled healthy or obese subjects

Exclusion Criteria

* PWS subjects without molecular confirmation of the diagnosis
* Subjects receiving glucocorticoid treatment within 3 months of evaluation
* Subjects receiving growth hormone within one year prior to analysis

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes